ERBB2 and gastric cancer: Moreover, AP-2α facilitates the epithelial–mesenchymal transition (EMT) in gastric cancer with amplification of the erb-b2 receptor tyrosine kinase 2 (ERBB2), whose molecular characteristics highlight AP-2α as a potential target for individuals resistant to anti-ERBB2 therapies, thereby expanding the horizon of AP-2α-targeted treatments [15].